Business Wire

SMOKE FREE SWEDEN: DANSKE RESTRIKTIONER PÅ NIKOTINPOSER VIL FÅ 150.000 TIL AT VENDE TILBAGE TIL RYGNING

Del

Et foreslået forbud mod ni ud af ti nikotinposer i Danmark vil være et massivt tilbageskridt i kampen mod tobak og vil tvinge titusindvis af tidligere rygere tilbage til dødelige cigaretter, advarer førende internationale eksperter i dag.

Reguleringer på sundhedsområdet, som vil blive fremlagt for Folketinget fredag den 11. oktober, vil begrænse nikotinniveauet i en nikotinpose til 9 mg – langt under internationale standarder og kun en brøkdel af nikotinniveauet i cigaretter.

Dr. Delon Human, en global ekspert i skadereduktion og leder af ”Smoke Free Sweden”, siger: "Nikotinposer er bevist at være et langt sikrere alternativ til cigaretter og hjælper millioner af rygere med at stoppe over hele verden.”

"Forslaget, som Folketinget skal behandle, vil forbyde 90 % af de poser, der aktuelt bruges i Danmark, hvilket efterlader rygerne med valget mellem de få tilbageværende poser eller cigaretter, der indeholder 85 % mere nikotin.

"Det er ikke svært at forudsige, hvilket valg de vil ende med at træffe. Rygere, der overvejer at stoppe, vil blive nægtet et levedygtigt og sikrere alternativ, mens størstedelen af de 153.000 nuværende brugere af nikotinposer vil blive presset tilbage til cigaretter.

"At gøre den farligste måde at indtage nikotin på til den mest attraktive er simpelthen ulogisk og et massivt tilbageskridt i den fortsatte kamp mod tobakkens dødelige konsekvenser."
Danmarks naboland Sverige har vist, at en progressiv tilgang til skadesreducerende røgfrie nikotinprodukter er den bedste vej til at udrydde rygning og de sundhedskonsekvenser, som følger med.

Sverige har oplevet et ekstraordinært fald i antallet af rygere på 55 % over det seneste årti og er på nippet til officielt at blive erklæret røgfrit efter WHO’s målsætning. Sammenlignet med resten af EU har Sverige nu 44 % færre tobaksrelaterede dødsfald og en 41 % lavere kræftrate.
Sveriges succes tilskrives den udbredte brug af orale nikotinprodukter med forskellige nikotinstyrker og smagsvarianter samt regeringens politik med at lægge højere afgifter på cigaretter end på røgfrie nikotinprodukter.

Det danske forslag har til hensigt at forbyde de lange cigaretter, som i øjeblikket bruges af en tredjedel af rygerne, samtidig med at nikotinindholdet i poser begrænses.
"Forbuddet mod 30 % af cigaretterne på markedet burde være en stor mulighed for at opmuntre rygere til at skifte til sikrere alternativer som nikotinposer," siger Dr. Human. "I stedet forsøger forslagene at gøre poser ineffektive og mindre tiltalende end cigaretter.

"Som i Sverige bør den danske regering anerkende den vigtige rolle, disse skadesreducerede nikotinprodukter spiller i at hjælpe rygere med at overgå fra røgtobak og gøre sikrere alternativer tilgængelige, acceptable og til at betale."

Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20241006970721/da/

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

FieldBee Vision wins Gold for Digital Technology Innovation at LAMMA 20269.1.2026 05:25:00 CET | Press release

FieldBee, the European leader in high-quality, easy-to-use and affordable precision agriculture technologies, proudly announces that FieldBee Vision has earned global recognition, becoming the Gold Winner in the Digital Technology Innovation of the Year category at the LAMMA Innovation Awards 2026. Lamma Show is the UK’s premier agricultural machinery, technology and equipment innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107606411/en/ FieldBee wins the LAMMA Innovation Award 2026 for Digital Technology Innovation of the Year for the FieldBee Vision (VisionSteer & VisionPro) system FieldBee Vision is part of the newly launched myFieldBee ecosystem, built to unify FieldBee’s precision farming tools and designed to connect navigation, autosteering, ISOBUS into one unified platform that supports planning, execution, monitoring and reporting. FieldBee Vision, the first modular retrofit agricultural vision system,

Survey Finds Over 70% of Chinese Doctors Recommend “AI Doctor Services” Like Ant Group’s AQ for Everyday Health Needs9.1.2026 04:31:00 CET | Press release

A recent survey by Life Times, a well-known Chinese public health media outlet, shows that AI doctor services are broadly supported by doctors in China. Among 500 physicians from the country’s top-tier (tertiary) hospitals, more than 70% said they would recommend AI doctor services to patients for everyday health questions and routine health management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108456917/en/ Ant Group’s AI-native health app AQ is designed to address common, everyday health concerns and support healthy habit formation. Ant Group’s AQ was the most frequently recommended platform in the survey. The latest figures show that, as of January 2026, the app had accumulated 30 million monthly active users and answers over 10 million health-related questions daily, making it China’s leading AI-native health app. AQ—known in Chinese as Ant A-Fu—is an AI-native health app launched by Ant Group in June 2025. Desig

OPPO Joins VVC Advance Patent Pool as a Licensee and Extends HEVC Advance License9.1.2026 03:00:00 CET | Press release

Access Advance LLC and Guangdong OPPO Mobile Telecommunications Corp., Ltd. (OPPO) today announced that OPPO has joined the VVC Advance Patent Pool as a Licensee and renewed its HEVC Advance License. OPPO, one of the world's largest smartphone manufacturers with operations in more than 70 countries, has been a valued participant in Access Advance's HEVC patent pool since 2020, and more recently joined the Advance Video Distribution Patent (VDP) Pool as a Licensor. These latest agreements mark a new milestone in a broad and deepening relationship between the two companies, with OPPO now participating across all three of Access Advance's video codec licensing programs. The VVC Advance Patent Pool licenses patents essential to the VVC/H.266 standard, which delivers remarkable improvement of video compression performance over HEVC, enabling higher-quality video experiences including 4K, 8K, and HDR content with faster downloads and lower latency. The pool currently includes over 4,500 worl

Cessna Citation CJ3 Gen2 Enters Into Service, Delivering the Most Significant Gen2 Updates to Date8.1.2026 22:30:00 CET | Press release

The Cessna Citation CJ3 Gen2 has entered into service, setting a new standard for the Citation Gen2 family. Launch customers and longtime Citation owners Dave Mecartney and Shannon Day took delivery of their new aircraft this week. Mecartney—an experienced aviator with nearly two decades flying Citation light jets and a member of Textron Aviation’s Customer Advisory Board—helped shape the enhancements that elevate the CJ3 Gen2 experience. Key upgrades include Garmin autothrottle technology, added pilot legroom and a fully customizable cabin environment, all driven by customer feedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108455097/en/ Cessna Citation CJ3 Gen2 enters into service, delivering the most significant Gen2 updates to date (Photo credit: Textron Aviation). The Cessna Citation CJ3 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The Citation CJ3 Gen2 deliv

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye